Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
NCT04580420
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Hyperoxaluria Type 1
End Stage Renal Disease
Interventions
DRUG:
DCR-PHXC
Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company